Replimune investors may seek lead plaintiff role in federal securities class action.

Faruqi & Faruqi is investigating potential claims against Replimune Group, a biotechnology company, for securities fraud. The investigation involves investors who purchased Replimune securities between November 22, 2024 and July 21, 2025. A federal securities class action has been filed against the company, and the deadline to seek the role of lead plaintiff is September 22, 2025. Investors who suffered losses can contact Josh Wilson, a partner at Faruqi & Faruqi, directly at 877-247-4292 or 212-983-9330.

Faruqi & Faruqi, LLP, a leading national securities law firm, has announced an investigation into potential claims against Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company. The investigation focuses on investors who purchased Replimune securities between November 22, 2024, and July 21, 2025. A federal securities class action has been filed against the company, with a September 22, 2025, deadline for investors to seek the role of lead plaintiff.

The complaint alleges that Replimune and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material information. Specifically, the complaint claims that the company recklessly overstated the prospects of the IGNYTE trial, which resulted in the FDA deeming the trial inadequate and not well-controlled. Consequently, investors suffered damages when the true details entered the market.

On July 22, 2025, Replimune issued a press release stating that the FDA had issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The CRL indicated that the FDA could not approve the application in its present form due to the IGNYTE trial's inadequacy. This news led to a significant drop in Replimune's common stock, plummeting over 73% during intraday trading on July 22, 2025.

Investors who suffered losses due to Replimune's securities are encouraged to contact Josh Wilson, a partner at Faruqi & Faruqi, directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Replimune's conduct to contact the firm, including whistleblowers, former employees, shareholders, and others. For more information about the Replimune class action, visit www.faruqilaw.com/REPL.

References:
[1] https://www.prnewswire.com/news-releases/faruqi--faruqi-reminds-replimune-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-22-2025---repl-302525489.html
[2] https://www.morningstar.com/news/pr-newswire/20250809ny47607/faruqi-faruqi-reminds-replimune-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-22-2025-repl